Revolutionary Glaucoma Detection: Beyond Pressure Monitoring

Glaucoma, often called the "silent thief of sight," typically presents no symptoms until significant vision loss has occurred. Traditional screening focuses primarily on intraocular pressure, but VisionScan's approach is far more comprehensive.

Multi-Modal Risk Assessment

Our AI analyzes optic nerve appearance, retinal nerve fiber layer thickness, visual field patterns, and vascular changes. This holistic approach identifies at-risk patients years before conventional methods would detect glaucoma.

The Pressure Paradox

Approximately 40% of glaucoma patients have "normal" eye pressure, while many people with elevated pressure never develop glaucoma. VisionScan's algorithms account for this complexity, providing personalized risk assessments rather than relying on pressure thresholds alone.

Detecting Progression

The system creates detailed baseline maps of each patient's optic nerve and retinal structure. Follow-up scans are automatically compared to baseline and previous images, with the AI detecting changes as small as 2 micrometers—far beyond human visual capacity.

Clinical Validation

A multi-center study published in the Journal of Ophthalmology demonstrated that VisionScan detected glaucoma an average of 3.2 years earlier than standard clinical examination. This early detection window is crucial for preserving vision.

Treatment Optimization

For patients already diagnosed with glaucoma, VisionScan's monitoring capabilities help optimize treatment. The AI can detect subtle progression that might prompt treatment adjustment, or confirm that current therapy is effectively controlling the disease.

Who Should Be Screened?

While everyone over 40 should have regular eye exams, VisionScan screening is particularly important for African Americans over 40, everyone over 60, people with family history of glaucoma, and individuals with high myopia or diabetes.